The US IPO market showed signs of losing momentum as two companies postponed planned listings, highlighting a growing gap between issuer valuation expectations and what public-market investors are currently willing to pay. After the IPO market rallied 42% in the second quarter, companies have continued preparing deals at elevated valuations, while investors are increasingly seeking the traditional IPO discount amid choppier market conditions.

Market Overview

The latest market activity suggests that demand for new listings has not disappeared, but pricing has become a more significant issue. With numerous companies that went public between 2024 and 2026 now trading at more attractive levels, investors have less incentive to stretch valuations for newly listed businesses.

Renaissance Capital’s assessment points to a normalization of IPO conditions following the strong second-quarter rally. Postponements attributed to “adverse market conditions” have emerged as companies and investors adjust to a market environment that is less supportive of aggressive pricing.

Private companies with strong fundamentals may still have access to investor demand, but companies with the ability to remain private can also delay listings while waiting for more favorable market conditions. Anthropic, for example, is now targeting November for its potential IPO.

This Past Week: ADARx Gains 13.8%

Biotechnology remained a notable area of IPO activity during the week. ADARx Pharmaceuticals (Nasdaq: ADRX), the week’s sole US IPO, raised $446 million and gained 13.8% following its debut.

The company develops RNA interference-based therapies, while AbbVie invested an additional $100 million. The participation of a major pharmaceutical company provides another element for investors to consider as pharmaceutical partnerships and potential M&A activity remain relevant to the biotechnology IPO market.

At the same time, Bamboo Insurance postponed its planned US listing. The CVC-backed homeowners insurance company had faced a challenging setup following Orion180’s IPO in the previous week. Renaissance Capital also noted that insiders planned to sell 100% of the Bamboo offering at a $3.3 billion market capitalization, less than a year after investing at a $1.8 billion valuation.

Next Week: Oura and Accelevation

Two closely watched IPO candidates are expected to test investor demand in the coming week: smart-ring maker Oura and AI infrastructure company Accelevation.

Oura plans to raise approximately $2.1 billion at a market capitalization approaching $15 billion. The company has been expanding rapidly and has moved toward profitability, although it enters a competitive wearable-device market. The history of prominent hardware companies such as Fitbit and Peloton also provides context for investors evaluating the durability of consumer-device growth.

Oura is also notable for its distribution to retail investors. Robinhood is listed as an underwriter, while Coinbase is serving as a selling agent.

Accelevation (Nasdaq: ACCV) is targeting a $660 million IPO and operates in power distribution products, making its offering a test of investor demand for infrastructure associated with artificial intelligence and data-center expansion. Its business has been compared with Forgent Power, which has gained 44% from its IPO price.

IPO Index Performance

The Renaissance IPO Index gained 2.2% through September 25, compared with a 1.2% gain for the S&P 500. Within the index, Astera Labs led the weekly gains with a 20.2% increase following the launch of new memory-connectivity products and a broader rally in semiconductor stocks.

BillionToOne gained 16.2%, BETA Technologies advanced 14.1%, Birkenstock Holding rose 9.9%, and Medline increased 9.7%.

On the downside, Jersey Mike’s Subs declined 13.2%, followed by Bending Spoons at 12.7%, Chime Financial at 11.7%, Fervo Energy at 10.2%, and Figure Technology Solutions at 10.1%.

Sector Performance

Health Care led the sectors represented in the Renaissance IPO Index, gaining 3.8% during the period. Technology increased 0.7%, while Industrials declined 0.8%.

Consumer Discretionary and Real Estate each fell 1.0%, followed by Consumer Staples at 3.9% lower and Financials at 5.4% lower. Energy declined 7.7%, while Utilities recorded the largest sector decline at 10.2%.

The sector performance shows that the IPO market remains uneven, with gains concentrated in selected healthcare and technology names while several other areas experienced declines.

Risks & Challenges

The central challenge for the IPO market is the gap between private-market valuation expectations and public-market pricing. Companies that prepared offerings during stronger market conditions may now need to reconsider pricing, deal structures or timing as investors reassess valuations.

Recent IPO performance also indicates that an AI-related narrative alone may not be sufficient to generate strong post-IPO performance. Companies entering the market must contend with existing public companies that may already offer investors exposure to similar growth themes at lower valuations.

For issuers, postponing an IPO can provide additional time to wait for market conditions to improve, but it can also delay access to public capital and extend uncertainty around the timing of a listing.

Closing Paragraph

The US IPO market enters the fall with investor demand still present but with greater sensitivity to valuation and pricing. ADARx’s strong debut, the postponement of Bamboo Insurance and the upcoming offerings from Oura and Accelevation illustrate the contrasting conditions facing companies seeking public capital. With the Renaissance IPO Index gaining 2.2% for the week, the market remains active, but the latest developments point toward a more selective environment for new listings.